Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

Hisashi Wada, Midori Isobe, Kazuhiro Kakimi, Yu Mizote, Shingo Eikawa, Eiichi Sato, Nagio Takigawa, Katsuyuki Kiura, Kazuhide Tsuji, Keiji Iwatsuki, Makoto Yamasaki, Hiroshi Miyata, Hirokazu Matsushita, Heiichiro Udono, Yasuyuki Seto, Kazuhiro Yamada, Hiroyoshi Nishikawa, Linda Pan, Ralph Venhaus, Mikio OkaYuichiro Doki, Eiichi Nakayama

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We conducted a clinical trial of an NY-ESO-1 cancer vaccine using 4 synthetic overlapping long peptides (OLP; peptides #1, 79-108; #2, 100-129; #3, 121-150; and #4, 142-173) that include a highly immunogenic region of the NY-ESO-1 molecule. Nine patients were immunized with 0.25 mg each of three 30-mer and a 32-mer long NY-ESO-1 OLP mixed with 0.2 KE Picibanil OK-432 and 1.25 mL Montanide ISA-51. The primary endpoints of this study were safety and NY-ESO-1 immune responses. Five to 18 injections of the NY-ESO-1 OLP vaccine were well tolerated. Vaccine-related adverse events observed were fever and injection site reaction (grade 1 and 2). Two patients showed stable disease after vaccination. An NY-ESO-1-specific humoral immune response was observed in all patients and an antibody against peptide #3 (121-150) was detected firstly and strongly after vaccination. NY-ESO-1 CD4 and CD8 T-cell responses were elicited in these patients and their epitopes were identified. Using a multifunctional cytokine assay, the number of single or double cytokine-producing cells was increased in NY-ESO-1-specific CD4 and CD8 T cells after vaccination. Multiple cytokine-producing cells were observed in PD-1 (-) and PD-1 (+) CD4 T cells. In conclusion, our study indicated that the NY-ESO-1 OLP vaccine mixed with Picibanil OK-432 and Montanide ISA-51 was well tolerated and elicited NY-ESO-1-specific humoral and CD4 and CD8 T-cell responses in immunized patients.

Original languageEnglish
Pages (from-to)84-92
Number of pages9
JournalJournal of Immunotherapy
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • CT antigen
  • NY-ESO-1
  • TLR
  • overlapping peptide vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen'. Together they form a unique fingerprint.

  • Cite this

    Wada, H., Isobe, M., Kakimi, K., Mizote, Y., Eikawa, S., Sato, E., Takigawa, N., Kiura, K., Tsuji, K., Iwatsuki, K., Yamasaki, M., Miyata, H., Matsushita, H., Udono, H., Seto, Y., Yamada, K., Nishikawa, H., Pan, L., Venhaus, R., ... Nakayama, E. (2014). Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Journal of Immunotherapy, 37(2), 84-92. https://doi.org/10.1097/CJI.0000000000000017